AUSTRALIS CAPITAL INC - AUSAF STOCK NEWS

Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) announces a positive corporate update highlighting anticipated revenue growth exceeding double for the fiscal year ended March 31, 2021. Key developments include expected closure of a land sale adding C$2.5 million to working capital, strategic expansion into the New York and East Coast cannabis markets, and the establishment of a Diversity & Inclusion Advisory Board. The company's subsidiary ALPS continues to grow its contract pipeline, with total Capex projects nearing $5 billion. AUSA aims to leverage the SAFE Banking Act for increased capital access.

Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) will be presenting live at VirtualInvestorConferences.com on April 20, 2021, at 3 PM EST. Jon Paul, the CFO, will engage with investors, answering questions in real-time. Investors can pre-register for the event, and an archived webcast will be available afterward. Recently, the company announced a $6 million contract with Copperstate Farms and appointed Dr. Jason Dyck as Chief Science Officer. These milestones signify AUSA's strategic growth in the cannabis industry.

Australis Capital Inc. (AUSAF) has announced a two-year agreement with Copperstate Farms, Arizona's largest cannabis wholesaler, to enhance its greenhouse operations in Snowflake, Arizona. The contract, valued at up to $6 million, includes upgrades to technology and cultivation practices aimed at increasing yield and product quality. Phase 1 focuses on upgrading existing facilities, while Phase 2 involves expanding the greenhouse by 40 acres, utilizing ALPS' advanced solutions. This collaboration aims to position Copperstate Farms as a significant player in the U.S. cannabis market, enhancing shareholder value.

Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) has appointed Dr. Jason Dyck as Chief Science Officer and Chairman of its Scientific Advisory Board. This strategic move aims to strengthen the company's focus on medical and wellness applications of cannabis. Dr. Dyck brings extensive experience from his tenure at Aurora Cannabis and has created the largest medical cannabis patient database in the world. He will guide scientific efforts and explore partnerships to enhance AUSA's innovation in the cannabis sector.

Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) has completed the initial phase of acquiring Green Therapeutics LLC (GT), marking its entry as a cannabis operator in the U.S. The transaction adds high-margin revenues through GT's award-winning brands and establishes a multi-state footprint expansion. AUSA plans to accelerate growth via new product development, market entry into new jurisdictions, and synergistic integration with existing operations. The acquisition is contingent on regulatory approval in Nevada and aims to enhance shareholder value significantly.

Australis Capital Inc. (AUSA) announced a definitive agreement to acquire Green Therapeutics LLC (GT) on March 11, 2021. This strategic acquisition, worth between C$8 million and C$10 million, aims to enhance AUSA's high-margin revenues and expand its multi-state operations. The deal will also resolve previous litigation by unwinding an earlier transaction. With award-winning GT products and licenses in Nevada, Oklahoma, and Missouri, AUSA looks to scale operations, boost revenue through licensing agreements, and strengthen its competitive position in the cannabis market.

Australis Capital Inc. (CSE: AUSA) has completed a $12 million acquisition of a 51% stake in 2750176 Ontario Inc. (ALPS), a leader in horticultural services, positioning AUSA for significant revenue growth. With this acquisition, Terry Booth becomes CEO and Dr. Duke Fu is appointed COO. The deal is expected to be accretive and enhance AUSA's portfolio through ALPS's established customer relationships. Revenue targets for ALPS range from $26.1 to $46.6 million, with EBITDA targets between $11.7 to $21.0 million, creating a robust financial outlook for AUSA's expansion in the cannabis market.

Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) has entered a joint venture with 3 Rivers Biotech for commercial-scale tissue culture aimed at cannabis, hemp, and traditional crops. In this partnership, AUSA will hold 15% and 3 Rivers 85%. The venture will leverage 3 Rivers' innovative plant tissue culture technologies, expected to enhance growers' economic returns and reduce risks associated with crop failure. The market potential is substantial, with hundreds of thousands of acres cultivated for cannabis and hemp in North America and Europe.

Australis Capital Inc. hosted a conference call on March 2, 2021, to discuss its Q3 2021 financial results. During the call, the company outlined its acquisition strategy, including a 51% acquisition of ALPS and a potential full acquisition of Green Therapeutics LLC. These moves are part of AUSA's effort to establish itself as a competitive player in the U.S. and global cannabis markets. A recording will be available on the company's website.